Search results
Showing 61 to 75 of 166 results for infarction
Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
Evidence-based recommendations on off-pump coronary artery bypass grafting. This involves attaching a healthy blood vessel to the heart muscle so that blood can get round (‘bypass’) the affected part of the coronary artery.
View recommendations for IPG377Show all sections
Sections for IPG377
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions (MIB295)
NICE has developed a medtech innovation briefing (MIB) on ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions .
Totally endoscopic robotically assisted coronary artery bypass grafting (IPG128)
Evidence-based recommendations on totally endoscopic robotically assisted coronary artery bypass grafting (TECAB). This involves using small, remote-controlled robotic arms to carry out the grafting procedure.
View recommendations for IPG128Show all sections
Sections for IPG128
Evidence-based recommendations on percutaneous laser coronary angioplasty. This involves using a laser to burn away the deposits blocking the blood vessels of the heart.
View recommendations for IPG378Show all sections
Sections for IPG378
Drug-eluting stents for the treatment of coronary artery disease (TA152)
Evidence-based recommendations on using drug-eluting stents in adults.
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making
Familial hypercholesterolaemia: identification and management (CG71)
This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)
This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure that the most effective treatments are offered. It includes guidance on follow-up care and information for people (aged 16 and over) who have had an aneurysmal subarachnoid haemorrhage, their families and carers.
Digital platforms to support cardiac rehabilitation: early value assessment (HTG764)
Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.
HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (HTG429)
Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.